Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
France
France- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
23 trials match your criteria
Recruiting
Investigational
Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo
Investigational
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:Dnth103
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Dnth103
Recruiting
Relapsing-remitting multiple sclerosis
RecruitingRegistered drugNo placebo
Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Relapsing-remitting multiple sclerosis
- Substances:Dimethyl FumarateDiroximel Fumarate+7
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Dimethyl Fumarate
Recruiting
Plasma cell myeloma
RecruitingRegistered drugNo placebo
Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:DaratumumabElranatamab+1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Daratumumab
Recruiting
Polycythaemia vera+4
RecruitingRegistered drugNo placebo
Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms
Registered drugNo placebo
- Disease:Polycythaemia veraEssential thrombocythaemia+3
- Substances:Acetylsalicylic AcidApixaban+1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid
Recruiting
Uveitis+1
RecruitingRegistered drugNo placebo
Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease
Registered drugNo placebo
- Disease:UveitisBehcet's syndrome
- Substances:AdalimumabTocilizumab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Adalimumab
Recruiting
B-cell lymphoma+1
RecruitingInvestigationalNo placebo
Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma
InvestigationalNo placebo
- Disease:B-cell lymphomaB-cell lymphoma refractory
- Substances:Valemetostat Tosilate
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Valemetostat Tosilate
Recruiting
Raynaud's phenomenon
RecruitingRegistered drug
Study on Clopidogrel's Effect in Preventing Systemic Sclerosis for Patients with Raynaud's Phenomenon and Specific Immune Conditions
Registered drug
- Disease:Raynaud's phenomenon
- Substances:Clopidogrel
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Clopidogrel
Not yet recruiting
Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations
Not yet recruitingRegistered drugNo placebo
Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations
Registered drugNo placebo
- Substances:NemtabrutinibObinutuzumab+1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Nemtabrutinib
Not yet recruiting
Ischaemic stroke
Not yet recruitingRegistered drugNo placebo
Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy
Registered drugNo placebo
- Disease:Ischaemic stroke
- Substances:Tenecteplase
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Tenecteplase
Not yet recruiting
Neuromyelitis optica spectrum disorder+1
Not yet recruitingRegistered drugNo placebo
Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab
Registered drugNo placebo
- Disease:Neuromyelitis optica spectrum disorderMultiple sclerosis
- Substances:OcrelizumabRituximab+1
Countries:France
France- Participants:18–64 years
- Substances:Ocrelizumab
Not yet recruiting
Breast cancer female
Not yet recruitingRegistered drugNo placebo
Study of abemaciclib and its connection to severe diarrhea in patients with hormone receptor-positive breast cancer at high risk of return
Registered drugNo placebo
- Disease:Breast cancer female
- Substances:Abemaciclib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Abemaciclib